Researchers develop new drug Lenvatinib that can slow progression of Thyroid Cancer

February 13, 2015 1:23 PM

17 0

A new thyroid cancer drug can slow the progression of the disease almost five times as compared to placebo in a new clinical trial. The new molecule, lenvatinib is a targeted therapy which deters the formation of blood vessels from which the cancerous tissues derives its nutrition.

Lenvatinib deterred the progression of advanced thyroid cancer by 18 months as compared to patients treated with placebo.

Read more

To category page